No Improvement in Overall Survival Between Patients with KRAS G12C NSCLC and Patients with non-KRAS G12C NSCLC

Web Exclusives —May 24, 2022


Lung Cancer

Lung cancer is the most common cause of cancer-related mortality worldwide with non–small-cell lung cancer (NSCLC) accounting for 85% of all cases.1 Kirsten rat sarcoma viral oncogene (KRAS) is a common mutation in NSCLC, accounting for 20% of all NSCLC cases. KRAS mutations are related to tobacco exposure, with only 5% of KRAS mutations found in light smokers or people who have never smoked.1 NSCLC cancer which harbors the KRAS mutation has a poor response to chemotherapy as KRAS mutation has the ability to alter the tumor microenvironment.1 The most common KRAS mutation occurs on codon 12.1 These mutations are associated with a poor overall patient prognosis, but with the development and use of immunotherapy, clinical outcomes for patients with KRAS-mutant NSCLC has improved.1

To evaluate the clinical outcomes of patients with KRAS-harboring NSCLC treated with immunotherapy, a retrospective study was performed using data from 120 patients treated at the Catalan Institute of Oncology in Badalona, Spain between 2013 and 2020. The cobas® KRAS mutation test was used to determine the KRAS status of these patients. This real-time PCR test detects mutations in codons 12, 13, and 61 of the KRAS gene. The cases in 2020 had KRAS status determined by next-generation sequencing. In addition to determining KRAS mutation, the patient’s PD-L1 status was determined and categorized as negative (<1%,) low (1%-49%), and high (50%-100%).

The median patient age at diagnosis was 63 years and 75% of all patients were male. Current or former smokers made up 96% of the patient cohort. Stage IV lung adenocarcinoma was present at first diagnosis for 74% of the patients and KRAS status was determined for 107 patients. When KRAS and PD-L1 were analyzed, 46% had KRAS G12C, 54% had non-G12C, and high PD-L1 was found in 37% of cases. The majority of the high PD-L1 cases were in KRAS G12C cases. Immunotherapy was instituted for 65 patients: 42% of these patients had immunotherapy as first-line therapy, 46% had it as second-line therapy, and 12% received immunotherapy as third-line therapy. Anti–PD-1 therapy was given to 81% of patients and 3% had anti–CTLA-4 therapy. Median progression-free survival to immunotherapy was 10.1 months for patients with KRAS G12C and 3.3 months for non-G12C (P = .07). Median overall survival for patients with KRAS G12C was 17.9 months and 18.6 months for patients with non-G12C KRAS (P = .13).


Notario Rincon L, Pous A, López-Paradís A, et al. The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): differences between KRAS G12C and non-G12C. Ann Oncol. 2022;33:s50.


  1. Xie M, Xu X, Fan Y. KRAS-mutant non-small cell lung cancer: an emerging promisingly treatable subgroup. Front Oncol. 2021;11:672612.
Related Articles
Importance of Early Detection in Lung Cancer: Elevating the Navigator’s Role
July 2022 Vol 13, No 7
With a malignancy like lung cancer, early detection can quite literally mean the difference between life and death. Despite this, lung cancer screening and incidental pulmonary nodule (IPN) management are still sorely lacking in the United States, according to Kim Parham, BSN, RN, CB-BN, vice president, Strategic Partnerships and Clinical Liaison, Thynk Health, and Shawn Perkins, BSN, RN, OCN, a thoracic services nurse navigator at Cone Health Cancer Center at Alamance Regional.
2022 Midyear Review: Non–Small-Cell Lung Cancer
Special Issues and Supplements
Anxiety and Depression in Advanced Lung Cancer Patients Affected by Symptoms and Therapy
Web Exclusives
Anxiety and depression in patients with advanced lung cancer are associated with poor outcomes when untreated. Radiotherapy, breathlessness, and fatigue are among top predictors of these debilitating conditions.
Last modified: May 24, 2022

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address Line 2
    Zip Code